PAI Partners and Carlyle completed the acquisition of Theramex from CVC Capital for $1.4bn.

PAI Partners and Carlyle, two investment firms, completed the acquisition of Theramex, a specialty pharmaceuticals company, from CVC Capital, a private equity and investment advisory firm, for $1.4bn. “We were attracted to Theramex given its strong heritage in women’s health and outstanding reputation for delivering effective and safe solutions that support and care for women around the world. We look forward to leveraging PAI’s extensive healthcare network and capital to support organic and inorganic growth initiatives for Theramex and partnering with the management team to support the continued expansion of the platform,” Sebastien Veil and Andreas Kumeth, PAI Partners.